Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Metastatic non-small cell lung cancer (NSCLC) classically portends a poor prognosis and worse overall survival. However, recent advances in modern systemic therapy and the increasing recognition of a distant clinical entity known as “oligometastatic disease”—i.e., a controlled primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Patricia Mae G., Li, Xingzhe, Gomez, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406686/
https://www.ncbi.nlm.nih.gov/pubmed/36010969
http://dx.doi.org/10.3390/cancers14163977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406686/
https://www.ncbi.nlm.nih.gov/pubmed/36010969
http://dx.doi.org/10.3390/cancers14163977

Ejemplares similares